-
公开(公告)号：US06399096B1
公开(公告)日：2002-06-04
申请号：US09043321
申请日：1998-07-27
申请人： Ronald Brown Miller , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Hassan Mohammad
发明人： Ronald Brown Miller , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Hassan Mohammad
IPC分类号： A61K920
CPC分类号： A61K9/2095 , A61K9/1617 , A61K9/1641 , A61K9/2013 , A61K31/485
摘要： A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.
摘要翻译： 固体，口服释放药物剂型具有分散在基质中的水溶性活性成分，并且在给药时以这样的速率释放活性成分，使得中值t max为2.5至6小时，平均C max与平均血浆水平的比率 的活性成分在24小时的范围是1.5-3.5。
-
公开(公告)号：US08506998B2
公开(公告)日：2013-08-13
申请号：US11640749
申请日：2006-12-18
申请人： Ronald Brown Miller , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Hassan Mohammad
发明人： Ronald Brown Miller , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Hassan Mohammad
CPC分类号： A61K9/2095 , A61K9/1617 , A61K9/1641 , A61K9/2013 , A61K31/485
摘要： A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.
-
公开(公告)号：US20070098795A1
公开(公告)日：2007-05-03
申请号：US11640749
申请日：2006-12-18
申请人： Ronald Brown Miller , Stewart Thomas Leslie , Santa Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Hassan Mohammad
发明人： Ronald Brown Miller , Stewart Thomas Leslie , Santa Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Hassan Mohammad
IPC分类号： A61K31/485 , A61K9/22
CPC分类号： A61K9/2095 , A61K9/1617 , A61K9/1641 , A61K9/2013 , A61K31/485
摘要： A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.
摘要翻译： 固体，口服释放药物剂型具有分散在基质中的水溶性活性成分，并且在给药时以这样的速率释放活性成分，使中值t max为2.5至6小时，平均C max与平均血浆水平的比率 的活性成分在24小时的范围是1.5-3.5。
-
公开(公告)号：US5843480A
公开(公告)日：1998-12-01
申请号：US774229
申请日：1996-12-27
申请人： Ronald Brown Miller , Stewart Thomas Leslie , Derek Allan Prater , Trevor John Knott , Hassan Mohammad
发明人： Ronald Brown Miller , Stewart Thomas Leslie , Derek Allan Prater , Trevor John Knott , Hassan Mohammad
IPC分类号： A61K31/135 , A61K31/485 , A61K9/14
CPC分类号： A61K31/485 , A61K31/135 , Y10S514/812
摘要： A controlled-release pharmaceutical preparation comprising diamorphine, or a pharmaceutically acceptable salt thereof.
摘要翻译： 包含二氢吗啡的控释药物制剂或其药学上可接受的盐。
-
5.发明授权Sustained release compositions and a method of preparing pharmaceutical compositions 有权持续释放组合物和制备药物组合物的方法
公开(公告)号：US6162467A
公开(公告)日：2000-12-19
申请号：US370270
申请日：1999-08-09
申请人： Ronald Brown Miller , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Joanne Heafield , Deborah Challis
发明人： Ronald Brown Miller , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Joanne Heafield , Deborah Challis
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/26 , A61K9/28 , A61K9/48 , A61K31/135 , A61K31/485
CPC分类号： A61K9/1617 , A61K9/1641 , A61K9/2013 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/2095 , A61K9/2866 , A61K31/135 , A61K31/485
摘要： A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.
摘要翻译： 用于制造颗粒的方法包括以高速混合物机械加工药物和疏水和/或亲水性熔融载体的混合物，以形成附聚物，破碎附聚物以产生控制释放颗粒，并且可选地继续机械加工 任选地加入低百分比的载体或稀释剂。
-
6.发明授权Sustained release compositions and a method of preparing pharmaceutical compositions 有权持续释放组合物和制备药物组合物的方法
公开(公告)号：US6143328A
公开(公告)日：2000-11-07
申请号：US264399
申请日：1999-03-08
申请人： Joanne Heafield , Trevor John Knott , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Ronald Brown Miller , Derek Allan Prater , Kevin John Smith
发明人： Joanne Heafield , Trevor John Knott , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Ronald Brown Miller , Derek Allan Prater , Kevin John Smith
IPC分类号： A61K9/16 , A61K9/20 , A61K9/26 , A61K9/28 , A61K31/135 , A61K31/485 , A61K9/14 , A61K9/52
CPC分类号： A61K31/485 , A61K31/135 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2866
摘要： Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35 to 150.degree. C.
摘要翻译： 公开了含有吗啡或其药学上可接受的盐作为活性成分的持续释放药物制剂，其适用于每天一次给药。 在第一方面，口服给药的持续释放单元剂型在给药后1.0至6小时给出峰值血浆水平。 在第二方面，所述制剂为4-50小时的吗啡的M-6-G代谢产物提供W50。 第三方面涉及通过将包含药物活性物质的多颗粒压缩在熔点为35-150℃的疏水性可熔材料的基质中获得的药物单位剂型。
-
7.发明授权
公开(公告)号：US5879705A
公开(公告)日：1999-03-09
申请号：US843571
申请日：1997-04-18
申请人： Joanne Heafield , Trevor John Knott , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Ronald Brown Miller , Derek Allan Prater , Kevin John Smith
发明人： Joanne Heafield , Trevor John Knott , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Ronald Brown Miller , Derek Allan Prater , Kevin John Smith
IPC分类号： A61K9/16 , A61K9/20 , A61K9/26 , A61K9/28 , A61K31/135 , A61K31/485
CPC分类号： A61K31/485 , A61K31/135 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2095 , A61K9/2866
摘要： Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35.degree. to 150.degree. C.
摘要翻译： 公开了含有吗啡或其药学上可接受的盐作为活性成分的持续释放药物制剂，其适用于每天一次给药。 在第一方面，口服给药的持续释放单元剂型在给药后1.0至6小时给出峰值血浆水平。 在第二方面，所述制剂为4-50小时的吗啡的M-6-G代谢产物提供W50。 第三方面涉及通过将包含药学活性物质的多颗粒压缩在熔点为35至150℃的疏水性可熔材料的基质中获得的药物单位剂型。
-
8.发明授权Substained release compositions and a method of preparing pharmaceutical compositions 失效大量释放组合物和制备药物组合物的方法
公开(公告)号：US5965163A
公开(公告)日：1999-10-12
申请号：US944106
申请日：1997-09-30
申请人： Ronald Brown Miller , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Joanne Heafield , Deborah Challis
发明人： Ronald Brown Miller , Stewart Thomas Leslie , Sandra Therese Antoinette Malkowska , Derek Allan Prater , Trevor John Knott , Joanne Heafield , Deborah Challis
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/26 , A61K9/28 , A61K9/48 , A61K31/135 , A61K31/485
CPC分类号： A61K9/1617 , A61K31/135 , A61K31/485 , A61K9/1641 , A61K9/2013 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/2095 , A61K9/2866
摘要： A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.
摘要翻译： 用于制造颗粒的方法包括以高速混合物机械加工药物和疏水和/或亲水性熔融载体的混合物，以形成附聚物，破碎附聚物以产生控制释放颗粒，并且可选地继续机械加工 任选地加入低百分比的载体或稀释剂。
-
9.发明授权
公开(公告)号：US6068855A
公开(公告)日：2000-05-30
申请号：US817956
申请日：1997-08-18
IPC分类号： A61J3/06 , A61K9/02 , A61K9/16 , A61K9/26 , A61K9/52 , A61K31/138 , A61K31/485 , A61K47/06 , A61K47/14 , A61K47/34 , A61K47/46 , B01F17/52 , A61J3/02 , B29B0/00
CPC分类号： A61K9/1617 , A61K9/1694
摘要： A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.
摘要翻译： PCT No.PCT / GB95 / 02579 Sec。 371日期：1997年8月18日 102（e）日期1997年8月18日PCT提交1995年11月3日PCT公布。 公开号WO96 / 14059 日期1996年5月17日制造颗粒的方法包括在高速混合物中机械加工药物和疏水和/或亲水性易熔体载体的混合物，以形成附聚物，破碎附聚物以产生控制释放颗粒，并任选地连续 机械加工可选择添加低百分比的载体或稀释剂。
-
公开(公告)号：US6077532A
公开(公告)日：2000-06-20
申请号：US029151
申请日：1998-05-08
申请人： Sandra Therese Antoinette Malkowska , Derek Allan Prater , Stewart Thomas Leslie , Adrian Brown , Trevor John Knott
发明人： Sandra Therese Antoinette Malkowska , Derek Allan Prater , Stewart Thomas Leslie , Adrian Brown , Trevor John Knott
CPC分类号： A61K47/48184 , A61K9/1623 , A61K9/1652 , Y10S514/952
摘要： A process is provided for preparing a granular pharmnaceutical ion exchange resin composition that is readily dispersible in water by granulating an ion exchange resin, having a pharmacologically active ingredient bound thereto, with a particulate sugar or sugar alcohol. The process is characterised by the use of an aqueous solution of a sugar or sugar alcohol as a granulating medium.
摘要翻译： PCT No.PCT / GB96 / 02156 Sec。 371日期1998年5月8日 102（e）日期1998年5月8日PCT提交1996年9月2日PCT公布。 出版物WO97 / 09036 日期1997年3月13日提供了一种制备颗粒状药物离子交换树脂组合物的方法，其通过将具有药理活性成分的离子交换树脂与颗粒状糖或糖醇粒化而容易地分散在水中。 该方法的特征在于使用糖或糖醇的水溶液作为造粒介质。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.032 秒)
